Cytosorbents Crp (CTSO) financial statements
Cytosorbents Crp reported revenue of $37M in fiscal 2025, up 18.2% a year over 9 years.
Net income was -$8M and the operating margin -39.8%, against -140.0% in 2016.
Free cash flow was -$13M.
The diluted share count rose 145% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Cytosorbents Crp's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $15M | $23M | $25M | $41M | $43M | $35M | $31M | $36M | $37M |
| Cost of revenue | $4M | $6M | $7M | $7M | $11M | $11M | $14M | $9M | $11M | $11M |
| Gross profit | $6M | $10M | $15M | $18M | $30M | $32M | $21M | $22M | $25M | $26M |
| Research and development | $4M | $3M | $8M | $12M | $9M | $16M | $15M | $16M | — | — |
| Selling, general and admin | $12M | $15M | $21M | $22M | $28M | $36M | $34M | $38M | $34M | $36M |
| Operating income | -$11M | -$10M | -$16M | -$19M | -$10M | -$23M | -$32M | -$32M | -$16M | -$15M |
| Pre-tax income | -$12M | -$9M | -$18M | -$20M | -$9M | -$25M | -$34M | -$30M | -$22M | -$9M |
| Income tax | -$318,550 | -$676,739 | -$619,546 | -$1M | -$1M | -$736,003 | -$1M | -$813,739 | -$2M | -$401,000 |
| Net income | -$12M | -$8M | -$17M | -$19M | -$8M | -$25M | -$33M | -$29M | -$21M | -$8M |
| EPS (diluted) | -$0.46 | -$0.32 | -$0.56 | -$0.60 | -$0.20 | -$0.57 | -$0.75 | -$0.65 | -$0.38 | -$0.13 |
| Diluted shares | 25M | 28M | 31M | 32M | 39M | 43M | 44M | 45M | 54M | 62M |
| Gross margin | 67.9% | 63.6% | 66.7% | 70.5% | 73.0% | 74.4% | 59.8% | 70.6% | 69.9% | 71.5% |
| Operating margin | -140.0% | -65.0% | -69.3% | -76.0% | -25.3% | -52.7% | -90.9% | -102.8% | -46.2% | -39.8% |
| Net margin | -143.4% | -55.8% | -76.5% | -77.2% | -19.1% | -56.9% | -94.6% | -94.1% | -58.2% | -22.1% |
Balance sheet
Fiscal years, from Cytosorbents Crp's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $5M | $17M | $22M | $12M | $71M | $52M | $22M | $14M | $3M | $6M |
| Receivables | $1M | $2M | $4M | $4M | $5M | $5M | $6M | $6M | $7M | $8M |
| Inventory | $833,976 | $795,657 | $833,133 | $2M | $3M | $5M | $3M | $3M | $3M | $5M |
| Total current assets | $8M | $21M | $28M | $21M | $82M | $64M | $34M | $25M | $22M | $21M |
| Property, plant and equipment | $569,409 | $1M | $2M | $2M | $2M | $5M | $11M | $10M | $9M | $8M |
| Total assets | $10M | $24M | $34M | $27M | $90M | $90M | $63M | $53M | $47M | $44M |
| Total current liabilities | $4M | $8M | $7M | $10M | $10M | $14M | $10M | $14M | $10M | $10M |
| Long-term debt | $4M | $6M | $9M | $13M | $0 | — | $5M | $3M | $14M | $17M |
| Total liabilities | $8M | $14M | $17M | $24M | $11M | $27M | $28M | $29M | $36M | $38M |
| Shareholders' equity | $1M | $10M | $17M | $3M | $79M | $63M | $35M | $23M | $11M | $6M |
| Net debt | -$333,531 | -$7M | -$12M | $3M | -$71M | -$52M | -$17M | -$9M | $11M | $10M |
Cash flow
Fiscal years, from Cytosorbents Crp's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7M | -$6M | -$11M | -$17M | -$6M | -$14M | -$28M | -$22M | -$14M | -$12M |
| Capital spending | $140,724 | $990,673 | $671,970 | $698,165 | $708,395 | $4M | $6M | $538,115 | $284,000 | $164,000 |
| Free cash flow | -$7M | -$7M | -$12M | -$17M | -$6M | -$18M | -$34M | -$22M | -$15M | -$13M |
| Stock-based compensation | $3M | $3M | $4M | $2M | $4M | $4M | $3M | $4M | $4M | $3M |
| Net borrowing | $5M | $5M | $0 | $5M | -$15M | — | $5M | — | $10M | $2M |
| Free cash flow margin | -83.7% | -49.2% | -51.2% | -70.0% | -15.4% | -40.9% | -98.9% | -71.4% | -41.3% | -33.8% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CTSO.
Open CTSO in InvestinglyQuestions
What was Cytosorbents Crp's revenue in 2025?
$37M in fiscal 2025, from its 10-K filing.
How much free cash flow does Cytosorbents Crp generate?
-$13M in fiscal 2025 (operating cash flow minus capital spending).
From Cytosorbents Crp's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.